Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Language
Publication year range
1.
Vet Anim Sci ; 16: 100245, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35372707

ABSTRACT

Analogues of glucagon like peptide-1 (GLP-1) and other drugs that increase this peptide half-life are used worldwide in human medicine to treat type 2 diabetes mellitus (DM) and obesity. These molecules can increase insulin release and satiety, interesting effects that could also be useful in the treatment of domestic animals pathologies, however their use in veterinary medicine are still limited. Considering the increasing incidence of DM and obesity in cats and dogs, the aim of this review is to summarize the available information about the physiological and pharmacological actions of GLP-1 in domestic animals and discuss about its potential applications in veterinary medicine. In diabetic dogs, the use of drugs based on GLP-1 actions reduced blood glucose and increased glucose uptake, while in diabetic cats they reduced glycemic variability and exogenous insulin administration. Thus, available evidence indicates that GLP-1 based drugs could become alternatives to DM treatment in domestic animals. Nevertheless, current data do not provide enough elements to recommend these drugs widespread clinical use.

2.
Article in English | MEDLINE | ID: mdl-29535684

ABSTRACT

Organotins (OTs) are considered some of the most toxic chemicals introduced into aquatic environments by anthropogenic activities. They are widely used for agricultural and industrial purposes and as antifouling additives on boat hull's paints. Even though the use of OTs was banned in 2008, elevated levels of OTs can still be detected in aquatic environments. OTs' deleterious effects upon wildlife and experimental animals are well documented and include endocrine disruption, immunotoxicity, neurotoxicity, genotoxicity, and metabolic dysfunction. Crustaceans are key members of zooplankton and benthic communities and have vital roles in food chains, so the endocrine-disrupting effects of tributyltin (TBT) on crustaceans can affect other organisms. TBT can disrupt carbohydrate and lipid homeostasis of crustaceans by interacting with retinoid X receptor (RXR) and crustacean hyperglycemic hormone (CHH) signaling. Moreover, it can also interact with other nuclear receptors, disrupting methyl farnesoate and ecdysteroid signaling, thereby altering growth and sexual maturity, respectively. This compound also interferes in cytochrome P450 system disrupting steroid synthesis and reproduction. Crustaceans are also important fisheries worldwide, and its consumption can pose risks to human health. However, some questions remain unanswered. This mini review aims to update information about the effects of OTs on the metabolism, growth, and reproduction of crustaceans; to compare with known effects in mammals; and to point aspects that still needs to be addressed in future studies. Since both macrocrustaceans and microcrustaceans are good models to study the effects of sublethal TBT contamination, novel studies should be developed using multibiomarkers and omics technology.

3.
Front Microbiol ; 7: 126, 2016.
Article in English | MEDLINE | ID: mdl-26904003

ABSTRACT

The blue crab, Callinectes sapidus Rathbun, 1896, which is a commercially important trophic link in coastal ecosystems of the western Atlantic, is infected in both North and South America by C. sapidus Reovirus 1 (CsRV1), a double stranded RNA virus. The 12 genome segments of a North American strain of CsRV1 were sequenced using Ion Torrent technology. Putative functions could be assigned for 3 of the 13 proteins encoded in the genome, based on their similarity to proteins encoded in other reovirus genomes. Comparison of the CsRV1 RNA-dependent RNA polymerase (RdRP) sequence to genomes of other crab-infecting reoviruses shows that it is similar to the mud crab reovirus found in Scylla serrata and WX-2012 in Eriocheir sinensis, Chinese mitten crab, and supports the idea that there is a distinct "Crabreo" genus, different from Seadornavirus and Cardoreovirus, the two closest genera in the Reoviridae. A region of 98% nucleotide sequence identity between CsRV1 and the only available sequence of the P virus of Macropipus depurator suggests that these two viruses may be closely related. An 860 nucleotide region of the CsRV1 RdRP gene was amplified and sequenced from 15 infected crabs collected from across the geographic range of C. sapidus. Pairwise analysis of predicted protein sequences shows that CsRV1 strains in Brazil can be distinguished from those in North America based on conserved residues in this gene. The sequencing, annotation, and preliminary population metrics of the genome of CsRV1 should facilitate additional studies in diverse disciplines, including structure-function relationships of reovirus proteins, investigations into the evolution of the Reoviridae, and biogeographic research on the connectivity of C. sapidus populations across the Northern and Southern hemispheres.

4.
Arq Bras Endocrinol Metabol ; 54(4): 375-80, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20625649

ABSTRACT

UNLABELLED: INTRODUSTION: Sibutramine has been described as a drug recommended for treatment of obesity, since it has the ability to inhibit the reuptake of serotonin and noradrenaline in the central nervous system, thereby increasing energy expenditure. OBJECTIVE: Investigate the anxiogenic and anxiolytic effects of acute and chronic treatment with sibutramine in rats submitted to the task of the elevated plus-maze. METHODS: Diazepam was used as a positive control for the anxiolytic effect, and the task of the elevated plus-maze showed sensitivity to detect the effect. In the chronic treatment, sibutramine was ingested for a period of two months. RESULTS: The acute and chronic treatments at the studied dose, which is described to produce a maximum effect of anti-obesity in rats, did not interfere with anxiety. CONCLUSIONS: The acute and chronic administration of sibutramine is not related to anxiolytic or anxiogenic effects.


Subject(s)
Anti-Anxiety Agents/pharmacology , Anti-Obesity Agents/pharmacology , Anxiety/drug therapy , Cyclobutanes/pharmacology , Analysis of Variance , Animals , Anti-Anxiety Agents/adverse effects , Anti-Obesity Agents/adverse effects , Body Weight/drug effects , Disease Models, Animal , Male , Maze Learning/drug effects , Motor Activity/drug effects , Random Allocation , Rats , Rats, Wistar
5.
Arq. bras. endocrinol. metab ; 54(4): 375-380, jun. 2010. ilus, graf
Article in English | LILACS | ID: lil-550707

ABSTRACT

INTRODUSTION: Sibutramine has been described as a drug recommended for treatment of obesity, since it has the ability to inhibit the reuptake of serotonin and noradrenaline in the central nervous system, thereby increasing energy expenditure. OBJECTIVE: Investigate the anxiogenic and anxiolytic effects of acute and chronic treatment with sibutramine in rats submitted to the task of the elevated plus-maze. METHODS: Diazepam was used as a positive control for the anxiolytic effect, and the task of the elevated plus-maze showed sensitivity to detect the effect. In the chronic treatment, sibutramine was ingested for a period of two months. RESULTS: The acute and chronic treatments at the studied dose, which is described to produce a maximum effect of anti-obesity in rats, did not interfere with anxiety. CONCLUSIONS: The acute and chronic administration of sibutramine is not related to anxiolytic or anxiogenic effects.


INTRODUÇÃO: A sibutramina tem sido descrita como um fármaco recomendado para o tratamento da obesidade, uma vez que tem a capacidade de inibir a recaptação de serotonina e noradrenalina no sistema nervoso central, aumentando assim o gasto energético. OBJETIVO: Investigar os efeitos ansiogênico e ansiolítico dos tratamentos agudo e crônico com a sibutramina em ratos Wistar submetidos à tarefa do labirinto em cruz elevado. MÉTODOS: O diazepam foi usado como controle positivo para o efeito ansiolítico, e a tarefa do labirinto em cruz elevado apresentou sensibilidade para detectar o efeito. No tratamento crônico, a sibutramina foi ingerida por um período de dois meses. RESULTADOS: Os tratamentos agudo e crônico, na dose estudada, que é descrita para produzir um efeito de antiobesidade máxima em ratos, não interferem na ansiedade. CONCLUSÕES: As administrações aguda e crônica de sibutramina não estão relacionadas aos efeitos ansiolítico ou ansiogênico.


Subject(s)
Animals , Male , Rats , Anti-Anxiety Agents/pharmacology , Anti-Obesity Agents/pharmacology , Anxiety/drug therapy , Cyclobutanes/pharmacology , Analysis of Variance , Anti-Anxiety Agents/adverse effects , Anti-Obesity Agents/adverse effects , Body Weight/drug effects , Disease Models, Animal , Maze Learning/drug effects , Motor Activity/drug effects , Random Allocation , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...